ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the global introduction of CoolFit, the newest addition to the applicator platform for the CoolSculpting System, at the American Academy for Dermatology (AAD) annual meeting in Miami.
“We are committed to optimizing patient outcomes and are focused on providing additional applicators that are both more efficient and that treat a broader range of patients,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. “CoolFit’s configuration and larger treatment area provides physicians with even more options when assessing patients and developing truly customized treatment plans to achieve the desired results.”
CoolFit’s advanced engineering design features a flat applicator cup and 38 percent larger cooling plates than the CoolCore applicator. This enables treatment of different areas on more body types than ever before. With CoolFit, it is possible for more patients to take advantage of CoolSculpting’s unique cooling approach that selectively targets and destroys fat, something heat-based procedures cannot replicate.
“The CoolFit design allows me to treat harder to reach areas and, for the first time, longer fat bulges, which is attracting new patients to my practice,” said Brian Zelickson, MD, Medical Director of Zel Skin & Laser Specialists in Edina, Minn. “My CoolSculpting patients who are being treated with CoolFit are very satisfied with their individual results.”The fifth applicator to be introduced for use with CoolSculpting, the CoolFit applicator allows physicians to easily customize patients’ treatment plans, particularly in areas with longer and hard-to-reach fat bulges. “CoolFit really rounds out the CoolSculpting applicator platform and has been a welcome addition to my practice because of its versatility,” said Jay Burns, MD, Medical Director of EpiCentre Park Lane in Dallas and EpiCentre Legacy in Plano, Texas. “In combination, all the applicators broaden the scope of treatable patients and their respective outcomes.”